Theriva Biologics
TOVX----
Theriva Biologics (TOVX)
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States....
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Theriva Biologics Analyst Rating
View MoreForecast & Rating
May 6, 2026Price forecast
$2.501021.58%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy50.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Jul 7 at 07:05 AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- PUBT · Jul 7 at 07:01 AM
Theriva Biologics wins Spanish regulator clearance for VIRAGE2 VCN-01 pancreatic cancer trial
- benzinga_article · Jun 11 at 07:46 AM
Theriva Biologics shares are trading higher after the company announced the publication of clinical, translational results from VCN-01's Phase 1 clinical trial in Head & Neck Squamous Cell Carcinoma in Clinical Cancer Research journal.
- Tip Ranks · May 6 at 06:38 AM
Alliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)
- nasdaq · May 6 at 04:35 AM
Theriva Q1 Net Loss Narrows; Plans Dosing Feasibility Study Of VCN-01 In H2,2026;Stock Down
- Earnings Watch · May 5 at 03:47 PM
Theriva Biologics | 8-K: FY2026 Q1 Revenue: USD 300 K
